Alzheimer's Disease: Erythrocyte 2,3-diphosphoglycerate Content and Circulating Erythropoietin
| Autor: | Vesna Jelic, Petter Järemo, Homira Behbahani, Bengt Winblad, Alenka Jejcic, Magnus Oweling, Tasmin Shahnaz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Erythrocytes Disease Cohort Studies 03 medical and health sciences Diagnostic Self Evaluation 0302 clinical medicine Alzheimer Disease Internal medicine Medicine Dementia Humans Cognitive Dysfunction Diphosphoglycerate Cognitive impairment Erythropoietin Aged 2 3-Diphosphoglycerate Red Cell business.industry Hypoxia (medical) Middle Aged medicine.disease 030104 developmental biology Endocrinology Neurology Female Neurology (clinical) Hemoglobin medicine.symptom business 030217 neurology & neurosurgery Biomarkers medicine.drug |
| Zdroj: | Current Alzheimer research. 16(9) |
| ISSN: | 1875-5828 |
| Popis: | Background: Alzheimer’s Disease (AD) features the accumulation of β-amyloid in erythrocytes. The subsequent red cell damage may well affect their oxygen-carrying capabilities. 2,3- diphosphoglycerate (2,3-DPG) binds to the hemoglobin thereby promoting oxygen release. It is theorized that 2,3-DPG is reduced in AD and that the resulting hypoxia triggers erythropoietin (EPO) release. Methods & Objective: To explore this theory, we analyzed red cell 2,3-DPG content and EPO in AD, mild cognitive impairment, and the control group, subjective cognitive impairment. Results: We studied (i) 2,3-DPG in red cells, and (ii) circulating EPO in AD, and both markers were unaffected by dementia. Disturbances of these oxygen-regulatory pathways do not appear to participate in brain hypoxia in AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|